We have observed
14 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after November 17, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation
BENZOIC ACID SALT OF OTAMIXABAN
OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY
PHARMACEUTICAL COMPOSITION AND SOLID GALENIC FORM HAVING A HIGH DRONEDARONE CONTENT, AND METHOD FOR PREPARING SAME
DRONEDARONE FOR THE PREVENTION OF ATRIAL FIBRILLATION
DERIVATIVES OF N-[(1H-PYRAZOL-1-YL)ARYL]-1H-INDOLE OR 1H-INDAZOLE-3-CARBOXAMIDE, THEIR PREPARATION AND THEIR USE AS P2Y12 ANTAGONISTS
PROCESS FOR SYNTHESIZING KETO-BENZOFURAN DERIVATIVES
METHOD FOR SYNTHESIZING KETOBENZOFURAN DERIVATIVES
Derivatives of 1H-indole-3-carboxamide and their use as P2Y12 antagonists
Compositions and methods using hdm2 antagonist and mek inhibitor
DRONEDARONE FOR USE IN LEISHMANIASIS, FORMULATIONS AND ASSOCIATIONS FOR USE IN LEISHMANIASIS.
USE OF VEGFR-3 INHIBITORS FOR TREATING HEPATOCELLULAR CARCINOMA
OTAMIXABAN FOR USE IN THE TREATMENT OF NON-ST ELEVATION ACUTE CORONARY SYNDROME IN PATIENTS PLANNED TO UNDERGO CORONARY ARTERY BYPASS GRAFTING
USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR IN THE PREVENTION OF ATRIAL FIBRILLATION